
and commercialization of innovative diagnostic tools.
Ceres Nanosciences, founded in Manassas, Virginia, is a privately held life sciences company dedicated to the research, development, and commercialization of innovative diagnostic tools. The company's core mission is to enhance diagnostic capabilities through advanced nanotechnology, aiming to improve healthcare outcomes globally. Ceres Nanosciences offers a range of products focused on the early detection and monitoring of diseases, leveraging their proprietary Nanotrap® technology to capture and concentrate low-abundance biomarkers from biological samples.
Ceres Nanosciences has garnered attention from notable investors and partners within the biotechnology and healthcare sectors. The company has achieved significant milestones, including securing funding for research and development and forming strategic partnerships to expand the application of their diagnostic tools. Their impact is evident in the improved sensitivity and accuracy of diagnostic tests, contributing to earlier disease detection and better patient management.

Nanoscope Technologies

Nanopath
nanopathdx.com

NanoCytomics
nano-cytomics.com

NanoHybrids
nanohybrids.net

NanoDx

NanoEngineering

Nanotools Bioscience
nanotoolsbio.com

Nanomatronix
nanomatronix.com

NanoMosaic

Nanospectra Biosciences
nanospectra.com

Cerora
cerora.com

Nano Cures
nanocures.com

BioNanovations

Scintillation Nanotechnologies
sntnano.com

NanoMedTrix
Companies similar to Ceres Nanosciences include Nanoscope Technologies, Nanopath, NanoCytomics and NanoHybrids.
Ceres Nanosciences was founded in 2008.
Ceres Nanosciences' headquarters is located in Manassas, VA, US.
Ceres Nanosciences' most recent funding round was for $5M (USD) in September 2022.
As of Sep 9, 2022, Ceres Nanosciences has raised a total of $24.5M (USD).
Ceres Nanosciences has 45 employees as of Feb 5, 2024.